Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Rhea-AI Summary

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced the appointment of Phillip Hains as the new Chief Financial Officer (CFO), effective 31 January 2024. Mr. Hains has almost 30 years of experience in corporate secretarial, accounting, and general management. This follows the resignation of Kathryn Andrews, who has been CFO since 2014. The company expressed deep appreciation for Kathryn's contributions and looks forward to expanding the relationship with Phillip in 2024, a pivotal year for Alterity.

MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Phillip Hains as the Company’s new Chief Financial Officer (CFO), effective 31 January 2024.

Mr. Hains has served as the Company Secretary of Alterity since 2014, and his experience includes almost 30 years in corporate secretarial, accounting and general management through professional services firm Acclime and predecessor firm The CFO Solution.

The appointment of Mr. Hains follows the resignation of Kathryn Andrews, who has been CFO since 2014. Ms. Andrews has chosen to leave Alterity to pursue other interests and will continue to support the Company during the transition.

David Stamler, M.D., Chief Executive Officer of Alterity, commented, “On behalf of the Board of Directors and management team, we would like to express our deep appreciation to Kathryn for her valuable contributions to the Company during her tenure as CFO, and we wish her well for the future. We look forward to expanding our relationship with Phillip as we enter 2024 which will be a pivotal year for us.”

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.

Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Investor and Media Contacts:

Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064

U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

FAQ

Who is the new Chief Financial Officer of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)?

Phillip Hains has been appointed as the new Chief Financial Officer of Alterity Therapeutics, effective 31 January 2024.

How long has Kathryn Andrews been the CFO of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)?

Kathryn Andrews has been the CFO of Alterity Therapeutics since 2014 and has chosen to leave the company to pursue other interests.

What is Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) focused on?

Alterity Therapeutics is a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases.

Why did Kathryn Andrews resign as CFO of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)?

Kathryn Andrews chose to leave Alterity to pursue other interests.

Who is the CEO of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)?

David Stamler, M.D. is the Chief Executive Officer of Alterity Therapeutics.